Bfsg LLC Reduces Stake in Pfizer Inc. (NYSE:PFE)

Bfsg LLC reduced its position in Pfizer Inc. (NYSE:PFE) by 5.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,252 shares of the biopharmaceutical company’s stock after selling 8,552 shares during the period. Bfsg LLC’s holdings in Pfizer were worth $4,614,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter valued at $30,000. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer during the 3rd quarter valued at $34,000. VisionPoint Advisory Group LLC grew its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the last quarter. GoalVest Advisory LLC grew its holdings in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 811 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer during the 4th quarter valued at $36,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Down 2.6 %

Shares of PFE traded down $0.69 during mid-day trading on Thursday, reaching $25.58. The company’s stock had a trading volume of 13,281,112 shares, compared to its average volume of 41,508,195. The business has a fifty day moving average of $27.05 and a 200 day moving average of $28.50. The company has a market cap of $144.85 billion, a price-to-earnings ratio of 71.14, a price-to-earnings-growth ratio of 1.19 and a beta of 0.61. Pfizer Inc. has a 1 year low of $25.23 and a 1 year high of $40.37. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.57%. Pfizer’s payout ratio is 466.67%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PFE. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, April 15th. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Eleven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.